A patient with a stage IB (cT2aN0M0) <i>KIF5B-RET</i> fusion-positive NSCLC received 8 weeks of neoadjuvant selpercatinib at 160 mg twice daily followed by surgery. Here, KIF5B is linked to non-small cell lung carcinoma.